Vericel Corporation

VCEL Healthcare Biotechnology

Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

40.13 0.89 −2.17%
Market cap
$2.1B
P/E
83.6×
Fwd P/E
76.8×
Dividend yield
—
F-score
7/9
Altman Z
8.21
Beneish M
−2.53
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

121.04 112.53 74.81 92.69
P/S ratio
6.14 6.56 5.59 7.42
P/FCF ratio
77.98 73.25 34.40 36.85
P/Operating CF
71.95 120.74 99.70 140.35
P/B ratio
4.94 5.11 4.59 6.14
EV/Sales
5.68 6.13 5.15 6.94
EV/EBITDA
87.03 74.82 53.72 68.01
EV/FCF
72.18 68.39 31.70 34.50
Current Ratio
4.87 5.03 5.18 5.04
Net Debt/EBITDA
(21.23) (5.37) 30.47 (40.05)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
0.83% 0.89% 1.34% 1.08%
Free Cash Flow Yield
1.28% 1.37% 2.91% 2.71%
Free Cash Flow per Share
0.39 0.25 0.30 0.28
Book value per Share
6.37 7.04 7.02 7.25
Free Cash Flow
19.45 12.83 15.13 14.26
EV/EBIT
206.92 153.25 95.44 116.65
Other line items

Show all line items

Columns are period end dates